

## Interventional Radiology

### 1. MCG Criteria Used

#### Clinical Criteria: MCG Care Guidelines, 30th Edition

- Uterine Artery Embolization (MCG ORG: A-0287 AC, 30th Edition) \*Note: This category currently includes the uterine artery embolization guideline. Additional interventional radiology guidelines, including image-guided biopsy and percutaneous angioplasty, are to be incorporated as the corresponding MCG source guidelines are obtained.\*

#### Applicable CPT / HCPCS Codes:

| CPT / HCPCS Code | Description                                                                                      |
|------------------|--------------------------------------------------------------------------------------------------|
| 37243            | Vascular embolization or occlusion, for tumors, organ ischemia, or infarction                    |
| 37244            | Vascular embolization or occlusion, for arterial or venous hemorrhage or lymphatic extravasation |
| 75894            | Transcatheter therapy, embolization, radiologic supervision and interpretation                   |
| 75898            | Angiography through existing catheter for follow-up study after transcatheter therapy            |
| 36245-36248      | Selective catheter placement, arterial system, abdominal, pelvic, or lower extremity             |

### 2. Statement of Rationale

Akido Labs uses the criteria in MCG Care Guidelines (30th Edition) to supplement the general Medicare criteria regarding interventional radiology procedures, beginning with uterine artery embolization, where Medicare coverage criteria are not fully established or require additional clinical specificity. MCG criteria are used to ensure consistency in reviewing the conditions to be met for coverage of interventional radiology procedures and to determine when such services are medically necessary. Uterine artery embolization is a minimally invasive, uterus-sparing alternative to hysterectomy or myomectomy for symptomatic uterine fibroids and a treatment for uterine hemorrhage. In the eligible population it carries procedural risks including post-embolization syndrome, nontarget embolization, infection, and, relevant to fertility, effects on ovarian reserve. Absent consistent, evidence-based criteria, there is material risk of both inappropriate denial of a medically necessary uterus-sparing procedure and inappropriate approval where the indication is not met or where an alternative is more appropriate.

#### Potential Clinical Harms:

**Uterine Artery Embolization:** Inappropriate denial of uterine artery embolization in a patient with symptomatic fibroids who is an appropriate candidate, or in a patient with uterine hemorrhage requiring embolization, could deny a uterus-sparing treatment and force a more invasive surgical alternative or leave hemorrhage inadequately controlled. Conversely, inappropriate approval of embolization where the diagnosis is not confirmed, where malignancy has not been excluded, or

where the clinical circumstances favor an alternative exposes the patient to procedural risk, including post-embolization syndrome and nontarget embolization, without offsetting benefit.

### Clinical Benefits:

**Uterine Artery Embolization:** MCG criteria define the indications for uterine artery embolization, including symptomatic uterine fibroids with confirmed diagnosis and the control of uterine hemorrhage, and incorporate the appropriate diagnostic workup, including exclusion of malignancy where indicated. By tying the procedure to a confirmed indication and appropriate workup, these criteria directly mitigate both the harm of denying a uterus-sparing treatment to an appropriate candidate and the harm of exposing an inappropriate candidate to procedural risk, as identified above. The clinical benefits of using MCG Care Guidelines are highly likely to outweigh any clinical harms, including delayed or decreased access to services, because the criteria incorporate indication thresholds drawn from specialty society guidance and are unlikely to lead to inappropriate denials.

## 3. Explanation of Supplementation

**Basis for Use:** Original Medicare clinical criteria are not fully established and require supplementation to ensure consistent medical necessity determinations for interventional radiology procedures. While Medicare statutes establish the general 'reasonable and necessary' standard, they do not specify the clinical indications and thresholds (e.g., the confirmed diagnosis, symptom criteria, and diagnostic workup required for uterine artery embolization) needed to distinguish indicated from nonindicated procedures.

**Applicable Medicare References:** Social Security Act Section 1862(a)(1): 'Reasonable and necessary' standard Medicare Benefit Policy Manual, Chapter 6: Hospital Services Covered Under Part B (CMS IOM Publication 100-02) Medicare Benefit Policy Manual, Chapter 15: Covered Medical and Other Health Services (CMS IOM Publication 100-02) Medicare Program Integrity Manual, Chapter 6, Section 6.5 (CMS IOM Publication 100-08) Code of Federal Regulations: 42 CFR 410.32; 42 CFR 419.22; 42 CFR 422.101 Medicare Coverage Database: <https://www.cms.gov/medicare-coverage-database/search.aspx> For interventional radiology procedures, no specific NCD or LCD fully establishes clinical indication thresholds; Original Medicare criteria are not fully established, requiring supplementation. Within the above statutes and regulations, MCG criteria assist in determining the appropriateness of uterine artery embolization based on confirmed diagnosis, symptom criteria, and appropriate diagnostic workup. Use of these criteria helps ensure interventional radiology procedures are not incorrectly denied when medically appropriate, nor incorrectly approved when not reasonable and necessary, and may decrease inappropriate denials by creating a consistent set of evidence-based review criteria.

## 4. Summary of Clinical Evidence

\*Note: The following evidence summary is derived directly from MCG Care Guidelines, 30th Edition (guideline A-0287). The reference list below is drawn from that MCG guideline.\*

### Background

**Uterine Artery Embolization (MCG ORG: A-0287 AC)** Uterine artery embolization injects particles via the uterine arteries to block blood supply in order to stop uterine hemorrhage or to

shrink uterine leiomyomas (fibroids). It is performed by an interventional radiologist as a minimally invasive, uterus-sparing alternative to surgical management. Appropriate use requires a confirmed diagnosis and, for fibroid treatment, an appropriate diagnostic evaluation including exclusion of malignancy where clinically indicated.

### Evidence Summary

**Uterine Artery Embolization (MCG ORG: A-0287 AC)** This guideline (30th Edition) is supported by peer-reviewed articles and specialty society guidance establishing the indications for uterine artery embolization for symptomatic fibroids and uterine hemorrhage, the comparative role of embolization relative to surgical alternatives, and the procedure-associated risks that inform appropriate patient selection.

**Rationale (from MCG)** Use of this MCG care guideline helps the clinician identify patient-specific clinical factors that establish the medical necessity of uterine artery embolization. The evidence-based clinical criteria ensure patients receive the most appropriate care for their specific condition, reduce unnecessary risks, and provide a standard that can reduce disparities in care. These guidelines supplement but do not replace, modify, or supersede existing Medicare regulations or applicable NCDs or LCDs.

**Related CMS Coverage Guidance (as cited in MCG 30th Edition):** Code of Federal Regulations (CFR): 42 CFR 410.32; 42 CFR 419.22; 42 CFR 422.101; CMS IOM Publication 100-02, Medicare Benefit Policy Manual, Chapters 6 and 15; CMS IOM Publication 100-08, Medicare Program Integrity Manual, Chapter 6, Section 6.5; Medicare Coverage Database: <https://www.cms.gov/medicare-coverage-database/search.aspx>

### References with Citation Summary -- Uterine Artery Embolization (MCG ORG: A-0287 AC, 30th Edition)

1. Soro MP, Denys A, de Rham M, Baud D. Short & long term adverse outcomes after arterial embolisation for the treatment of postpartum haemorrhage: a systematic review. *European Radiology* 2017;27(2):749-62. DOI: 10.1007/s00330-016-4395-2. [ Context Link 1, 2, 3 ] View abstract...
2. Banayan JM, Hofer JE, Scavone BM. Antepartum and postpartum hemorrhage. In: Chestnut DH, et al., editors. *Chestnut's Obstetric Anesthesia*. 6th ed. Elsevier; 2020:901-936. [ Context Link 1, 2, 3 ]
3. Keung JJ, Spies JB, Caridi TM. Uterine artery embolization: A review of current concepts. *Best Practice and Research. Clinical Obstetrics and Gynaecology* 2018;46:66-73. DOI: 10.1016/j.bpobgyn.2017.09.003. [ Context Link 1, 2 ] View abstract...
4. Dariushnia SR, Nikolic B, Stokes LS, Spies JB, Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. *Journal of Vascular and Interventional Radiology* 2014;25(11):1737-1747. DOI: 10.1016/j.jvir.2014.08.029. (Reaffirmed 2025 Jul) [ Context Link 1, 2, 3, 4, 5, 6 ] View abstract...
5. Spies JB. Current role of uterine artery embolization in the management of uterine fibroids. *Clinical Obstetrics and Gynecology* 2016;59(1):93-102. DOI: 10.1097/GRF.000000000000162. [ Context Link 1 ] View abstract...
6. Moss J, Christie A. Uterine artery embolization for heavy menstrual bleeding. *Women's Health* 2016;12(1):71-7. DOI: 10.2217/whe.15.78. [ Context Link 1, 2, 3, 4 ] View abstract...
7. Makary MS, et al. Management of Uterine Fibroids. ACR Appropriateness Criteria [Internet] American College of Radiology (ACR). 2023 Accessed at: <https://www.acr.org/>. [accessed 2025 Apr 08] [ Context Link 1, 2, 3, 4 ]
8. Jeon GU, Jeon GS, Kim YR, Ahn EH, Jung SH. Uterine artery embolization for postpartum hemorrhage with placenta accreta spectrum. *Acta Radiologica* 2023;64(7):2321-2326. DOI: 10.1177/02841851231154675. [ Context Link 1 ] View abstract...
9. Silver RM, Branch DW. Placenta accreta spectrum. *New England Journal of Medicine* 2018;378(16):1529-1536. DOI: 10.1056/NEJMcp1709324. [ Context Link 1, 2 ] View abstract... [https://careweb.careguidelines.com/ed30/ac/ac03\\_149.htm](https://careweb.careguidelines.com/ed30/ac/ac03_149.htm) 3/5 6/29/26, 2:15 PM AC - Uterine Artery Embolization
10. Steins Bisschop CN, Schaap TP, Vogelvang TE, Scholten PC. Invasive placentation and uterus preserving treatment modalities: a systematic review. *Archives Gynecology and* 2011;284(2):491-

502. DOI: 10.1007/s00404-011-1934-6. [ Context Link 1 ] View abstract... Ambulatory Care >ofProcedures andObstetrics Diagnostic Tests > Obstetrics and Gynecology >Uterine Artery Embolization (A-0287)
11. Zhu YP, Sun ZJ, Lang JH, Pan J. Clinical characteristic and management of acquired uterine arteriovenous malformation. *Chinese Medical Journal* 2018;131(20):2489-2491. DOI: 10.4103/0366-6999.243570. [ Context Link 1, 2 ] View abstract...
  12. Peitsidis P, Manolakos E, Tsekoura V, Kreienberg R, Schwentner L. Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. *Archives of Gynecology and Obstetrics* 2011;284(5):1137-51. DOI: 10.1007/s00404-011-2067-7. [ Context Link 1 ] View abstract...
  13. Gizzo S, et al. Fertility rate and subsequent pregnancy outcomes after conservative surgical techniques in postpartum hemorrhage: 15 years of literature. *Fertility and Sterility* 2013;99(7):2097-107. DOI: 10.1016/j.fertnstert.2013.02.013. [ Context Link 1, 2 ] View abstract...
  14. Mei J, et al. Systematic review of uterus-preserving treatment modalities for abnormally invasive placenta. *Journal of Obstetrics and Gynaecology* 2015;1-6. DOI: 10.3109/01443615.2015.1011106. [ Context Link 1 ] View abstract...
  15. Sathe NA, Likis FE, Young JL, Morgans A, Carlson-Bremer D, Andrews J. Procedures and uterine-sparing surgeries for managing postpartum hemorrhage: a systematic review. *Obstetrical and Gynecological Survey* 2016;71(2):99-113. DOI: 10.1097/OGX.0000000000000273. [ Context Link 1, 2, 3 ] View abstract...
  16. Kellie FJ, Wandabwa JN, Mousa HA, Weeks AD. Mechanical and surgical interventions for treating primary postpartum haemorrhage. *Cochrane Database of Systematic Reviews* 2020, Issue 7. Art. No.: CD013663. DOI: 10.1002/14651858.CD013663. [ Context Link 1 ] View abstract...
  17. Bonsen LR, et al. Prophylactic radiologic interventions for postpartum hemorrhage control in women with placenta accreta spectrum disorder: a systematic review and meta-analysis. *Obstetrics & Gynecology* 2024;144(3):315-27. DOI: 10.1097/AOG.0000000000005662. [ Context Link 1 ] View abstract...
  18. Munoz JL, Blankenship LM, Ramsey PS, McCann GA. Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. *American Journal of Obstetrics and Gynecology* 2023;229(1):61.e1-61.e7. DOI: 10.1016/j.ajog.2023.03.028. [ Context Link 1 ] View abstract...
  19. Loya MF, Garcia-Reyes K, Gichoya J, Newsome J. Uterine artery embolization for secondary postpartum hemorrhage. *Techniques in Vascular and Interventional Radiology* 2021;24(1):100728. DOI: 10.1016/j.tvir.2021.100728. [ Context Link 1 ] View abstract...
  20. Ghanaati H, et al. Pregnancy rate and outcomes following uterine artery embolization for uterine arteriovenous malformations: a systematic review and meta-analysis. *Journal of Vascular and Interventional Radiology* 2023;34(7):1184-1191.e2. DOI: 10.1016/j.jvir.2023.03.015. [ Context Link 1 ] View abstract...
  21. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology. Management of symptomatic uterine leiomyomas: ACOG practice bulletin, number 228. Reaffirmed 2025. *Obstetrics & Gynecology* 2021;137(6):e100-e115. DOI: 10.1097/AOG.0000000000004401. (Reaffirmed 2025 Jun) [ Context Link 1, 2 ] View abstract...
  22. Clements W, Brown N, Buckley B, Rogan C, Kok HK, Liang E. Quality care guidelines for uterine artery embolisation in women with symptomatic uterine fibroids in Australia and New Zealand: According to the AGREE-II checklist and endorsed by the Interventional Radiology Society of Australasia. *Journal of Medical Imaging and Radiation Oncology* 2022;66(6):819-825. DOI: 10.1111/1754-9485.13455. [ Context Link 1 ] View abstract...
  23. Stewart EA. Uterine fibroids. *New England Journal of Medicine* 2015;372(17):1646-1655. DOI: 10.1056/NEJMcp1411029. [ Context Link 1, 2, 3, 4 ] View abstract...
  24. Fonseca MCM, Castro R, Machado M, Conte T, Girao MJBC. Uterine artery embolization and surgical methods for the treatment of symptomatic uterine leiomyomas: a systemic review and meta-analysis followed by indirect treatment comparison. *Clinical Therapeutics* 2017;39(7):14381455.e2. DOI: 10.1016/j.clinthera.2017.05.346. [ Context Link 1 ] View abstract...
  25. Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. *Cochrane Database of Systematic Reviews* 2014, Issue 12. Art. No.: CD005073. DOI: 10.1002/14651858.CD005073.pub4. [ Context Link 1 ] View abstract...

26. Hartmann KE, et al. Management of Uterine Fibroids. Comparative Effectiveness Review #195 AHRQ Publication No. 17(18)-EHC028-EF [Internet] Agency for Healthcare Research and Quality Effective Health Care Program. 2017 Dec Accessed at: <https://www.effectivehealthcare.ahrq.gov/>. [accessed 2025 Sep 04] DOI: 10.23970/AHRQEPCCER195. [ Context Link 1 ]
27. Tzanis AA, Antoniou SA, Gkegkes ID, Iavazzo C. Uterine artery embolization vs myomectomy for the management of women with uterine leiomyomas: a systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology* 2024;231(2):187-195. DOI: 10.1016/j.ajog.2024.01.014. [ Context Link 1 ] View abstract...
28. de Bruijn AM, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. *American Journal of Obstetrics and Gynecology* 2016;215(6):745.e1-e12. DOI: 10.1016/j.ajog.2016.06.051. [ Context Link 1 ] View abstract...
29. Manyonda I, et al. Uterine-artery embolization or myomectomy for uterine fibroids. *New England Journal of Medicine* 2020;383(5):440-451. DOI: 10.1056/NEJMoa1914735. [ Context Link 1 ] View abstract...
30. Boosz AS, Reimer P, Matzko M, Romer T, Muller A. The conservative and interventional treatment of fibroids. *Deutsches Arzteblatt International* 2014;111(51-52):877-83. DOI: 10.3238/arztebl.2014.0877. [ Context Link 1 ] View abstract...
31. Ito T, Mattingly PJ, Jan AG, Biscette SM, Kim JHJ. Alternatives to excisional therapy: a clinical review of our current options to conservatively manage symptomatic leiomyomas. *Current Opinion in Obstetrics and Gynecology* 2018;30(4):279-286. DOI: 10.1097/GCO.0000000000000470. [ Context Link 1 ] View abstract...
32. Committee on Practice Bulletins-Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. *Obstetrics & Gynecology* 2012 (ACOG reaffirmed 2024);120(1):197-206. DOI: 10.1097/AOG.0b013e318262e320. (Reaffirmed 2025 Jun) [ Context Link 1 ] View abstract... [https://careweb.careguidelines.com/ed30/ac/ac03\\_149.htm](https://careweb.careguidelines.com/ed30/ac/ac03_149.htm) 4/5 6/29/26, 2:15 PM AC - Uterine Artery Embolization
33. Kaunitz AM. Abnormal uterine bleeding in reproductive-age women. *Journal of the American Medical Association* 2019;321(21):2126-2127. DOI: 10.1001/jama.2019.5248. [ Context Link 1 ] View abstract... Ambulatory Care > Procedures and Diagnostic Tests > Obstetrics and Gynecology > Uterine Artery Embolization (A-0287)
34. Vannuccini S, Petraglia F, Carmona F, Calaf J, Chapron C. The modern management of uterine fibroids-related abnormal uterine bleeding. *Fertility and Sterility* 2024;122(1):20-30. DOI: 10.1016/j.fertnstert.2024.04.041. [ Context Link 1 ] View abstract...
35. Barat M, et al. Treatment of adenomyosis, abdominal wall endometriosis and uterine leiomyoma with interventional radiology: A review of current evidences. *Diagnostic and Interventional Imaging* 2024;105(3):87-96. DOI: 10.1016/j.diii.2023.11.005. [ Context Link 1 ] View abstract...
36. Committee on Practice Bulletins-Obstetrics. Postpartum hemorrhage. Practice Bulletin No. 183. *Obstetrics & Gynecology* 2017 (ACOG reaffirmed 2024);130(4):e168-e186. DOI: 10.1097/AOG.0000000000002351. (Reaffirmed 2025 Jun) [ Context Link 1, 2 ] View abstract...
37. Vilos GA, et al. The management of uterine leiomyomas. *Journal of Obstetrics and Gynaecology Canada* 2015;37(2):157-81. (Reaffirmed 2025 Jul) [ Context Link 1 ] View abstract...
38. Micic J, et al. Currently available treatment modalities for uterine fibroids. *Medicina (Kaunas, Lithuania)* 2024;60(6):DOI: 10.3390/medicina60060868. [ Context Link 1 ] View abstract...
39. Lee S, Stewart EA. New treatment options for nonsurgical management of uterine fibroids. *Current Opinion in Obstetrics and Gynecology* 2023;35(4):288-293. DOI: 10.1097/GCO.0000000000000880. [ Context Link 1 ] View abstract...
40. Centers for Medicare and Medicaid Services. "Hospital services excluded from payment under the hospital outpatient prospective payment system." 42 CFR 419.22 Washington, DC 2023 Jul [accessed 2025 Jul 22] Accessed at: <https://www.ecfr.gov/>. [ Context Link 1 ]
41. Centers for Medicare and Medicaid Services. "Requirements relating to basic benefits." 42 CFR 422.101 Washington, DC 2025 Jun 03 [accessed 2025 Jul 23] Accessed at: <https://www.ecfr.gov/>. [ Context Link 1 ]
42. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 - Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at:



<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2025 Sep 09]  
[ Context Link 1 ]

43. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services Rev. 13108 [Internet] Centers for Medicare and Medicaid Services. 2025 Apr 11 Accessed at: <https://www.cms.gov/manuals/>. [accessed 2025 Sep 09]  
[ Context Link 1 ]
44. Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 16 - General Exclusions From Coverage Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2025 Sep 09] [ Context Link 1 ]
45. Medicare Coverage Database. [Internet] Centers for Medicare and Medicaid Services. Accessed at: <https://www.cms.gov/medicare-coverage-database/search.aspx?> Updated 2025 [accessed 2025 Oct 23] [ Context Link 1 ]

## 5. Public Accessibility

**Transparency Tool URL:** <https://akido.access.mcg.com/index>

**Coverage Summaries URL:** <https://www.myfamilymg.com/medical-necessity-supplementation-criteria/documents>

**Navigation Instructions:** To access these coverage summaries, navigate to the UM Criteria page, scroll to the bottom of the page, and click the Medical Necessity Supplementation Criteria link. All summaries are organized alphabetically by category.